Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569847 | 1.00 | ACE2 (0.48) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL2332737 | 1.00 | ACE2 (0.48) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL28916786 | 1.00 | ACE2 (0.48) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL11668063 | 1.00 | ACE2 (0.48) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL6921288 | 1.00 | ACE2 (0.48) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL6569983 | 1.00 | ACE2 (0.48) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL3731166 | 1.00 | ACE2 (0.48) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL28706062 | 1.00 | ACE2 (0.48) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL5970293 | 1.00 | ACE2 (0.48) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL27574613 | 1.00 | ACE2 (0.48) | ACE2GPR84FFAR1MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152146-A1 | Methods for screening compounds for use in the treatment of disease | ENCORE PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | claimed |
| WO-2004055200-A2 | METHODS FOR SCREENING COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE | ENCORE PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | WO | claimed |
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SPRIASO LLC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9956201-B2 | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms | SPRIASO LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
| US-20040152146-A1 | Methods for screening compounds for use in the treatment of disease | ENCORE PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004055200-A2 | METHODS FOR SCREENING COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE | ENCORE PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SLC7A1, CYP2D6, SLC19A1 | ACE2 554/4885GPR84 4187/4885FFAR1 1717/4885 |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SLC7A1, CYP2D6, CYP3A7 | ACE2 543/4885GPR84 4555/4885FFAR1 2387/4885 |
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SLC7A1, CYP2D6, CYP3A7 | ACE2 535/4885GPR84 4443/4885FFAR1 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.